[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.211.168.204. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
From the Food and Drug Administration
May 2, 2001

Famotidine Labeling Change

Author Affiliations
 

Not Available

Not Available

JAMA. 2001;285(17):2186. doi:10.1001/jama.285.17.2186-JFD10004-3-1

The FDA has changed the labeling for prescription famotidine (Pepcid tablets; Pepcid for oral suspension; Pepcid RPD orally disintegrating tablets; and Pepcid injection and Pepcid injection premixed; Merck & Co Inc, Whitehouse Station, NJ), indicated for short-term treatment and maintenance therapy for duodenal ulcer; short-term treatment of active benign gastric ulcer, gastroesophageal reflux disease (GERD), and esophagitis due to GERD; and treatment of pathological hypersecretory conditions.

First Page Preview View Large
First page PDF preview
First page PDF preview
×